How important is HER-2 amplification in the treatment of breast cancer?
HER-2 amplification and subsequent overexpression of the gene product have emerged as a key prognostic and therapeutic marker in breast cancer. Amplification of this gene is found to be associated with rapid proliferation, shorter disease-free survival and poorer overall survival in both node-negative and node-positive ductal breast cancers. With the advent of monoclonal targeted therapies such as Herceptin® ® (Trastuzumab), accurate HER-2 assessment is a critical component in determining appropriate therapy selection. Both the National Comprehensive Cancer Network (NCCN®) and the American Society of Clinical Oncology (ASCO®) recommend HER-2 assessment for all invasive breast cancers.
